Development of technology for assessing micronutrient intake using hair and provision of analysis services.
株式会社ノビアス（本社：東京都八王子市、代表取締役社長：藤野智子、以下「当社」）は、AIアルゴリズムおよびリアルタイム2D→3D変換に関する基盤技術に関する単独特許を出願したことをお知らせします。本特許は...
株式会社ノビアス（本社：東京都八王子市、代表取締役社長：藤野智子、以下「当社」）は、国立研究開発法人国立がん研究センター（所在地：東京都中央区、理事長：間野博行） 、地方独立行政法人総合病院国保旭中...
[画像1: https://prtimes.jp/i/82856/13/resize/d82856-13-7fa4358a5f61049455de-2.png ] 株式会社NOVIUS（東京都・八王子市）は、英国GlobalData社によって行われる表彰プログラム「Medical Device Network Exce...
研究の名称  AI技術を用いた透視画像の疑似3D化に関する多機関共同観察研究 研究概要： 平面的な透視画像を擬似3D化することにより、「手前」「奥」の認識がリアルタイムで可能となり、病変への誘導が容易...
研究課題：AI技術を用いた透視画像の擬似3D化 研究目的：平面的な透視画像をAI技術を用いてリアルタイムに２Dから疑似3D化することで、「手前」あるいは「奥」の認識が可能になり、気管支鏡の病変への誘導が容...
[画像: https://prtimes.jp/i/82856/7/resize/d82856-7-e5503534b86be284214e-1.png ]   ■Microsoft for Startupsとは 世界140カ国以上で展開されているマイクロソフト社が提供する新しい顧客やチャ...
株式会社NOVIUSがNVIDIA INCEPTION PROGRAMパートナー企業に認定 [画像: https://prtimes.jp/i/82856/4/resize/d82856-4-13ced2cf1bd9055cd7f5-0.png ] 株式会社NOVIUSが、GPUディープラーニングプラット...
bacterico is a biotechnology startup developing personalized healthcare solutions based on an individual’s own gut microbiome. We isolate, select, and cultivate Bifidobacterium strains from stool samples and enhance them using proprietary culture methods to create personalized probiotic supplements optimized for each person’s gut environment. We also provide evidence-based programs tailored to key life moments, including Mama Flora, which supports maternal and infant health through prenatal gut microbiome care, and Preflora, a personalized nutrition and gut-health program designed specifically for individuals who are actively trying to conceive. Through science-driven, individualized interventions, bacterico aims to bring safe and effective microbiome-based solutions to everyday health.
A startup advancing drug discovery through proprietary platform technology that selectively delivers drugs to immune cells, both through in-house development and collaborative partnerships. It aims to create novel therapies for intractable diseases by controlling immune responses.
For the 1.2 million patients with chronic heart failure in Japan, a wristwatch-type wearable device will be used to detect heart murmurs and changes in activity levels specific to heart failure and recommend that patients seek medical attention. After the consultation, doctors will adjust oral medication, ultimately reducing re-hospitalization due to worsening heart failure.
We develop and sell therapeutic drugs and skin care cosmetics, focusing on drug transdermal absorption technology that can absorb both water-soluble and hydrophobic compounds of large molecular weight. In particular, in joint research with Kobe University, we found that carbon dioxide transdermal absorption has an increase and activation effect on mitochondria, and it has been revealed that it can safely increase muscle strength, promote healing of wounds/fractures, and inhibit scarring, partial weight loss by promoting fat metabolism, and induce apoptosis in cancer cells. Some products are on the market not only in Japan but also in other countries.
